Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + paclitaxel
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sunitinib + paclitaxel is a combination of two pharmaceutical agents used in oncology clinical trials. Sunitinib is an oral small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor that blocks several RTKs involved in tumor growth, angiogenesis, and metastatic progression, including platelet-derived growth factor receptors (PDGFRs), vascular endothelial growth factor receptors (VEGFRs), KIT, FLT3, RET, and CSF-1R. Paclitaxel is a cytotoxic chemotherapeutic agent that stabilizes microtubules and inhibits cell division. The combination has been investigated for the treatment of advanced solid tumors such as metastatic breast cancer and angiosarcoma. Preclinical studies suggest enhanced anti-tumor activity through both antiangiogenic effects from sunitinib and cytotoxicity from paclitaxel[1][2][3].
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)GFRA4 (GDNF family receptor alpha-4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on sunitinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + paclitaxel.